Page last updated: 2024-12-06

isobutyramide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Isobutyramide is a simple amide derived from isobutyric acid. It is a white, crystalline solid with a melting point of 128-130 °C. It is soluble in water, ethanol, and acetone. Isobutyramide is typically synthesized by reacting isobutyric acid with ammonia.

It is used as a precursor to other organic compounds and has been investigated as a potential intermediate in the synthesis of various pharmaceuticals and agrochemicals. Isobutyramide has also been reported to have antibacterial activity against certain strains of bacteria. Further research is ongoing to explore its potential applications and biological effects.
'

Cross-References

ID SourceID
PubMed CID68424
CHEMBL ID352219
CHEBI ID193555
MeSH IDM0095740

Synonyms (41)

Synonym
EN300-17833
563-83-7
isobutyrimidic acid
nsc8423
isobutyramide ,
isobutylamide
nsc-8423
2-methylpropanamide
propanamide, 2-methyl-
2-methylpropionamide
NCI60_041854
nsc 8423
brn 1737615
einecs 209-265-9
inchi=1/c4h9no/c1-3(2)4(5)6/h3h,1-2h3,(h2,5,6
isobutyramide, 99%
AKOS001084432
CHEMBL352219
I0102
CHEBI:193555
dimethylacetoamide
unii-82uoe7b38z
4-02-00-00852 (beilstein handbook reference)
82uoe7b38z ,
FT-0672107
FT-0627380
68424-61-3
glycerides, c16-18 and c18-unsatd. mono- and di-
IBO ,
isobutyric acid amide
DTXSID1060340
mfcd00008019
SY015332
W-105521
c-isopropylformamide
CS-W019979
bdbm50224866
Q10859786
2-methyl-propanamide
1-carbamoyl-1-methylethyl
Z57046209

Research Excerpts

Treatment

ExcerptReferenceRelevance
"Isobutyramide treatment induced pronounced morphological changes in LNCaP tumor cells, with loss of defined nucleoli and dispersion of chromatin distribution."( Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model.
Bruchovsky, N; Gleave, ME; Sadar, M; Sato, N; Sullivan, L; Yago, V, 1998
)
1.35

Pharmacokinetics

ExcerptReferenceRelevance
" The half-life (t1/2) of VX-366 was more than 7 hours, and there was evidence of nonlinear pharmacokinetics."( Pharmacokinetics and safety of single oral doses of VX-366 (isobutyramide) in healthy volunteers.
Brettman, LR; Chaturvedi, PR, 1996
)
0.54

Bioavailability

The objectives of this study were to characterize the in vitro effects of sodium butyrate on human prostate cancer cell growth, PSA gene expression, and differentiation in the LNCaP tumor model. To determine whether tumor progression in vivo is delayed by isobutyramide, an orally bioavailable Bt analogue with a longer half-life.

ExcerptReferenceRelevance
" The objectives of this study were to characterize the in vitro effects of sodium butyrate on human prostate cancer cell growth, PSA gene expression, and differentiation in the LNCaP tumor model and to determine whether tumor progression in vivo is delayed by isobutyramide, an orally bioavailable butyrate analogue with a longer half-life."( Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model.
Bruchovsky, N; Gleave, ME; Sadar, M; Sato, N; Sullivan, L; Yago, V, 1998
)
0.81
" The objectives of our study were to characterize the in vitro effects of NaBt and/or docetaxel on the growth, cell cycle and apoptosis of human bladder cancer cells, and to determine whether tumor growth in vivo is inhibited by isobutyramide, an orally bioavailable Bt analogue, and/or docetaxel by using Bcl-2-transfected human bladder cancer cell line KoTCC-1/BH and control vector only-transfected cell line KoTCC-1/C."( Overexpression of Bcl-2 regulates sodium butyrate- and/or docetaxel-induced apoptosis in human bladder cancer cells both in vitro and in vivo.
Arakawa, S; Hara, I; Hara, S; Kamidono, S; Miyake, H, 2001
)
0.49
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
carboximidic acid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Alcohol dehydrogenase E chainEquus caballus (horse)Ki194.91200.14122.89278.7000AID33720; AID33855
Alcohol dehydrogenase S chainEquus caballus (horse)Ki194.91200.14122.89278.7000AID33720; AID33855
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID33720In vitro inhibition against horse liver alcohol dehydrogenase1983Journal of medicinal chemistry, Jun, Volume: 26, Issue:6
Inhibition by carboxamides and sulfoxides of liver alcohol dehydrogenase and ethanol metabolism.
AID33855Inhibitory activity against horse liver alcohol dehydrogenase (ADH)1986Journal of medicinal chemistry, May, Volume: 29, Issue:5
A quantitative structure-activity relationship and molecular graphics analysis of hydrophobic effects in the interactions of inhibitors with alcohol dehydrogenase.
AID183376In vivo inhibition of ethanol metabolism following 1 mMol/Kg p.o.1983Journal of medicinal chemistry, Jun, Volume: 26, Issue:6
Inhibition by carboxamides and sulfoxides of liver alcohol dehydrogenase and ethanol metabolism.
AID23467Partition coefficient (logP)1986Journal of medicinal chemistry, May, Volume: 29, Issue:5
A quantitative structure-activity relationship and molecular graphics analysis of hydrophobic effects in the interactions of inhibitors with alcohol dehydrogenase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (39)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (25.64)18.7374
1990's14 (35.90)18.2507
2000's7 (17.95)29.6817
2010's7 (17.95)24.3611
2020's1 (2.56)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.05

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index32.05 (24.57)
Research Supply Index3.83 (2.92)
Research Growth Index4.83 (4.65)
Search Engine Demand Index42.09 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (32.05)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (9.76%)5.53%
Reviews1 (2.44%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other36 (87.80%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]